Yuli Guzman-Prado1, Jennifer Ben Shimol2,3, Ondrej Samson4. 1. Clinical Research, International Centre for Medical Research, Dorset, UK. juliguzmanprado@outlook.com. 2. Department of Medicine, E. Wolfson Medical Center, Holon, Israel. 3. Sackler Faculty of Medicine, Tel Aviv University, Ramat Gan, Israel. 4. Alltrista, Christchurch, Dorset, UK.
Abstract
BACKGROUND: As a result of the growing use of immune checkpoint inhibitors (ICIs) for treating malignancy, immune-related adverse events (irAEs) have been increasingly reported. Higher body mass index (BMI) has been highlighted as a potential risk factor for the development of irAEs. However, there are no meta-analyses summarizing the association between BMI and irAEs in patients on ICI therapies. METHODS: PubMed, MEDLINE, EMBASE, Cochrane and grey literature were searched up to January 2020. Odds ratios (ORs) 95% and confidence intervals (CIs) were summarized using the random-effects model. Heterogeneity test, subgroup and sensitivity analyses were conducted. The protocol was registered on PROSPERO (number registration: CRD42020168790). RESULTS: Five studies (n = 1937) met eligibility criteria for inclusion. Being overweight or obese was associated with an increased odds of developing irAEs (OR 2.62, 95% CI 1.70-4.03, P ≤ 0.00001, I2 = 53%). In subgroup analyses, higher BMI was associated with irAEs in patients using anti-CTLA-4 single agents or in combination with anti-PD-1/PD-L1 (OR 1.87, 95% CI 1.17-2.98, P = 0.009, I2 = 0%) and in patients using anti-PD-1/PD-L1 (OR 3.22, 95% CI 2.06-5.01, P = 0.00001, I2 = 32%) monotherapy. The increased odds of irAEs in patients with higher BMI was comparable (test for subgroup differences, P = 0.72, I2 = 0%) between studies with adjusted OR (OR 2.21, 95% CI 1.44-3.38, P = 0.0003, I2 = 4%) and unadjusted OR (OR 2.65, 95% CI 1.08-6.50, P = 0.03, I2 = 66%). CONCLUSION: Our meta-analysis provides evidence of a relationship between higher BMI (overweight-obesity) and increased risk of irAEs in patients on ICI therapies. Further research is needed to strengthen this association.
BACKGROUND: As a result of the growing use of immune checkpoint inhibitors (ICIs) for treating malignancy, immune-related adverse events (irAEs) have been increasingly reported. Higher body mass index (BMI) has been highlighted as a potential risk factor for the development of irAEs. However, there are no meta-analyses summarizing the association between BMI and irAEs in patients on ICI therapies. METHODS: PubMed, MEDLINE, EMBASE, Cochrane and grey literature were searched up to January 2020. Odds ratios (ORs) 95% and confidence intervals (CIs) were summarized using the random-effects model. Heterogeneity test, subgroup and sensitivity analyses were conducted. The protocol was registered on PROSPERO (number registration: CRD42020168790). RESULTS: Five studies (n = 1937) met eligibility criteria for inclusion. Being overweight or obese was associated with an increased odds of developing irAEs (OR 2.62, 95% CI 1.70-4.03, P ≤ 0.00001, I2 = 53%). In subgroup analyses, higher BMI was associated with irAEs in patients using anti-CTLA-4 single agents or in combination with anti-PD-1/PD-L1 (OR 1.87, 95% CI 1.17-2.98, P = 0.009, I2 = 0%) and in patients using anti-PD-1/PD-L1 (OR 3.22, 95% CI 2.06-5.01, P = 0.00001, I2 = 32%) monotherapy. The increased odds of irAEs in patients with higher BMI was comparable (test for subgroup differences, P = 0.72, I2 = 0%) between studies with adjusted OR (OR 2.21, 95% CI 1.44-3.38, P = 0.0003, I2 = 4%) and unadjusted OR (OR 2.65, 95% CI 1.08-6.50, P = 0.03, I2 = 66%). CONCLUSION: Our meta-analysis provides evidence of a relationship between higher BMI (overweight-obesity) and increased risk of irAEs in patients on ICI therapies. Further research is needed to strengthen this association.
Authors: Maria C Harpsøe; Saima Basit; Mikael Andersson; Nete M Nielsen; Morten Frisch; Jan Wohlfahrt; Ellen A Nohr; Allan Linneberg; Tine Jess Journal: Int J Epidemiol Date: 2014-03-07 Impact factor: 7.196
Authors: Guy Ledergor; Assaf Weiner; Mor Zada; Shuang-Yin Wang; Yael C Cohen; Moshe E Gatt; Nimrod Snir; Hila Magen; Maya Koren-Michowitz; Katrin Herzog-Tzarfati; Hadas Keren-Shaul; Chamutal Bornstein; Ron Rotkopf; Ido Yofe; Eyal David; Venkata Yellapantula; Sigalit Kay; Moshe Salai; Dina Ben Yehuda; Arnon Nagler; Lev Shvidel; Avi Orr-Urtreger; Keren Bahar Halpern; Shalev Itzkovitz; Ola Landgren; Jesus San-Miguel; Bruno Paiva; Jonathan J Keats; Elli Papaemmanuil; Irit Avivi; Gabriel I Barbash; Amos Tanay; Ido Amit Journal: Nat Med Date: 2018-12-06 Impact factor: 53.440
Authors: Amanda Leiter; Emily Carroll; Sonia De Alwis; Danielle Brooks; Jennifer Ben Shimol; Elliot Eisenberg; Juan P Wisnivesky; Matthew D Galsky; Emily Jane Gallagher Journal: Eur J Endocrinol Date: 2021-05-10 Impact factor: 6.558
Authors: Dongyu Zhang; Neil J Shah; Michael Cook; Matthew Blackburn; Michael T Serzan; Shailesh Advani; Arnold L Potosky; Michael B Atkins; Dejana Braithwaite Journal: Cancers (Basel) Date: 2021-12-03 Impact factor: 6.575
Authors: Melissa L Bastacky; Hong Wang; Dylan Fortman; Zahra Rahman; Gerard P Mascara; Timothy Brenner; Yana G Najjar; Jason J Luke; John M Kirkwood; Hassane M Zarour; Diwakar Davar Journal: Front Oncol Date: 2021-11-26 Impact factor: 6.244
Authors: Julie R Brahmer; Hamzah Abu-Sbeih; Paolo Antonio Ascierto; Jill Brufsky; Laura C Cappelli; Frank B Cortazar; David E Gerber; Lamya Hamad; Eric Hansen; Douglas B Johnson; Mario E Lacouture; Gregory A Masters; Jarushka Naidoo; Michele Nanni; Miguel-Angel Perales; Igor Puzanov; Bianca D Santomasso; Satish P Shanbhag; Rajeev Sharma; Dimitra Skondra; Jeffrey A Sosman; Michelle Turner; Marc S Ernstoff Journal: J Immunother Cancer Date: 2021-06 Impact factor: 13.751
Authors: Pepijn W A Thomas; Tessa E H Römkens; Rachel L West; Maurice G V M Russel; Jeroen M Jansen; Jette A van Lint; Naomi T Jessurun; Frank Hoentjen Journal: United European Gastroenterol J Date: 2021-06-02 Impact factor: 4.623